Correction: Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4–NDRG1 axis (Cancer Research (2017) 77 (86–99) DOI: 10.1158/0008-5472.CAN-16-1797)

Nandini Verma; Anna Katharina Muller; Charu Kothari; Effrosini Panayotopoulou; Amir Kedan; Michael Selitrennik; Gordon B. Mills; Lan K. Nguyen; Sungyoung Shin; Thomas Karn; Uwe Holtrich; Sima Lev

doi:10.1158/0008-5472.CAN-19-3573

Correction: Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4–NDRG1 axis (Cancer Research (2017) 77 (86–99) DOI: 10.1158/0008-5472.CAN-16-1797)

Nandini Verma, Anna Katharina Muller, Charu Kothari, Effrosini Panayotopoulou, Amir Kedan, Michael Selitrennik, Gordon B. Mills, Lan K. Nguyen, Sungyoung Shin, Thomas Karn, Uwe Holtrich, Sima Lev

Research output: Contribution to journal › Comment / Debate › Other › peer-review

1 Citation (Scopus)

Abstract

In the original version of this article (1), two instances of inadvertent duplication of crystal violet staining images occurred in Fig. 1D (control shRNA conditions in MDA-MB-468 and BT-20) and in Fig. 1F (0 mmol/L gefitinib control conditions in MDA-468 and BT-20). In addition, the same set of STAT3 Western blot bands was inadvertently duplicated in Fig. 3A (BT-20 and HCC1937). These errors have been corrected in the latest online HTML and PDF versions of the article. The authors regret these errors.

Original language	English
Pages (from-to)	362
Number of pages	1
Journal	Cancer Research
Volume	80
Issue number	2
DOIs	https://doi.org/10.1158/0008-5472.CAN-19-3573
Publication status	Published - 15 Jan 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1158/0008-5472.CAN-19-3573

Cite this

Verma, N., Muller, A. K., Kothari, C., Panayotopoulou, E., Kedan, A., Selitrennik, M., Mills, G. B., Nguyen, L. K., Shin, S., Karn, T., Holtrich, U., & Lev, S. (2020). Correction: Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4–NDRG1 axis (Cancer Research (2017) 77 (86–99) DOI: 10.1158/0008-5472.CAN-16-1797). Cancer Research, 80(2), 362. https://doi.org/10.1158/0008-5472.CAN-19-3573

@article{36f33462c633438690df378d4130def6,

title = "Correction: Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4–NDRG1 axis (Cancer Research (2017) 77 (86–99) DOI: 10.1158/0008-5472.CAN-16-1797)",

abstract = "In the original version of this article (1), two instances of inadvertent duplication of crystal violet staining images occurred in Fig. 1D (control shRNA conditions in MDA-MB-468 and BT-20) and in Fig. 1F (0 mmol/L gefitinib control conditions in MDA-468 and BT-20). In addition, the same set of STAT3 Western blot bands was inadvertently duplicated in Fig. 3A (BT-20 and HCC1937). These errors have been corrected in the latest online HTML and PDF versions of the article. The authors regret these errors.",

author = "Nandini Verma and Muller, {Anna Katharina} and Charu Kothari and Effrosini Panayotopoulou and Amir Kedan and Michael Selitrennik and Mills, {Gordon B.} and Nguyen, {Lan K.} and Sungyoung Shin and Thomas Karn and Uwe Holtrich and Sima Lev",

year = "2020",

month = jan,

day = "15",

doi = "10.1158/0008-5472.CAN-19-3573",

language = "English",

volume = "80",

pages = "362",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research (AACR)",

number = "2",

}

Verma, N, Muller, AK, Kothari, C, Panayotopoulou, E, Kedan, A, Selitrennik, M, Mills, GB, Nguyen, LK , Shin, S, Karn, T, Holtrich, U & Lev, S 2020, 'Correction: Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4–NDRG1 axis (Cancer Research (2017) 77 (86–99) DOI: 10.1158/0008-5472.CAN-16-1797)', Cancer Research, vol. 80, no. 2, pp. 362. https://doi.org/10.1158/0008-5472.CAN-19-3573

Correction: Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4–NDRG1 axis (Cancer Research (2017) 77 (86–99) DOI: 10.1158/0008-5472.CAN-16-1797). / Verma, Nandini; Muller, Anna Katharina; Kothari, Charu et al.
In: Cancer Research, Vol. 80, No. 2, 15.01.2020, p. 362.

Research output: Contribution to journal › Comment / Debate › Other › peer-review

TY - JOUR

T1 - Correction

T2 - Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4–NDRG1 axis (Cancer Research (2017) 77 (86–99) DOI: 10.1158/0008-5472.CAN-16-1797)

AU - Verma, Nandini

AU - Muller, Anna Katharina

AU - Kothari, Charu

AU - Panayotopoulou, Effrosini

AU - Kedan, Amir

AU - Selitrennik, Michael

AU - Mills, Gordon B.

AU - Nguyen, Lan K.

AU - Shin, Sungyoung

AU - Karn, Thomas

AU - Holtrich, Uwe

AU - Lev, Sima

PY - 2020/1/15

Y1 - 2020/1/15

N2 - In the original version of this article (1), two instances of inadvertent duplication of crystal violet staining images occurred in Fig. 1D (control shRNA conditions in MDA-MB-468 and BT-20) and in Fig. 1F (0 mmol/L gefitinib control conditions in MDA-468 and BT-20). In addition, the same set of STAT3 Western blot bands was inadvertently duplicated in Fig. 3A (BT-20 and HCC1937). These errors have been corrected in the latest online HTML and PDF versions of the article. The authors regret these errors.

AB - In the original version of this article (1), two instances of inadvertent duplication of crystal violet staining images occurred in Fig. 1D (control shRNA conditions in MDA-MB-468 and BT-20) and in Fig. 1F (0 mmol/L gefitinib control conditions in MDA-468 and BT-20). In addition, the same set of STAT3 Western blot bands was inadvertently duplicated in Fig. 3A (BT-20 and HCC1937). These errors have been corrected in the latest online HTML and PDF versions of the article. The authors regret these errors.

UR - http://www.scopus.com/inward/record.url?scp=85077820145&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-19-3573

DO - 10.1158/0008-5472.CAN-19-3573

M3 - Comment / Debate

C2 - 31941679

AN - SCOPUS:85077820145

SN - 0008-5472

VL - 80

SP - 362

JO - Cancer Research

JF - Cancer Research

IS - 2

ER -

Verma N, Muller AK, Kothari C, Panayotopoulou E, Kedan A, Selitrennik M et al. Correction: Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4–NDRG1 axis (Cancer Research (2017) 77 (86–99) DOI: 10.1158/0008-5472.CAN-16-1797). Cancer Research. 2020 Jan 15;80(2):362. doi: 10.1158/0008-5472.CAN-19-3573

Correction: Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4–NDRG1 axis (Cancer Research (2017) 77 (86–99) DOI: 10.1158/0008-5472.CAN-16-1797)

Abstract

UN SDGs

Access to Document

Other files and links

Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4-NDRG1 axis

Cite this